Search | Clinical Trials Finder

Conditions: Lung Cancers
Interventions: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®), Intercostal nerve block; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: ROX Anastomotic Coupler System (ACS); Device
Lead sponsor: ROX Medical, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 5 more

Conditions: Nasal Obstruction, Medically Unexplained Symptoms, Airway Obstruction, Airway Remodeling
Interventions: VivAer Stylus; Device
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois • Skokie, Illinois

Conditions: Mechanical Ventilation, Pneumonia
Interventions: CAM (Complete Airway Management) Catheters; Device
Lead sponsor: O. M. Neotech, Inc.; Industry
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Cape Girardeau, Missouri

Conditions: Asthma
Interventions: CHF 1531 pMDI, Formoterol Inhalation Solution, Placebo pMDI; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Lutherville, Maryland + 7 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Inhaled PT001, Inhaled Placebo, Tiotropium Handihaler; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Peoria, Arizona • Denver, Colorado • Miami, Florida + 3 more

Conditions: Lung Neoplasms, Respiratory Failure, Pneumonia, Acute Coronary Syndromes, Unstable Angina, Myocardial Infarction, Cardiac Arrhythmia, Thromboembolic Disease
Interventions: Normal Saline, Sodium Bicarbonate; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep-disordered Breathing, Snoring
Interventions: CPAP; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Empty Nose Syndrome, Nasal Obstruction
Interventions: Personalized ART, Non-personalized ART; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 2
States / cities: Stanford, California • Columbus, Ohio

Conditions: Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Chronic Obstructive Pulmonary Disease, Asthma
Interventions: Not listed
Lead sponsor: Deep Breeze; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions: Sterotactic Body Radiotherapy/SBRT, Standard of care; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 9
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more

Conditions: Congenital Disorders
Interventions: Not listed
Lead sponsor: Children's Healthcare of Atlanta; Other
Eligibility: Up to 2 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1984 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cystic Fibrosis in Children
Interventions: spirometry; Diagnostic Test
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 5 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: Lakewood, California • Long Beach, California

Conditions: Nasal Airway Obstruction
Interventions: Novapak Nasal Sinus Packing and Stent; Device
Lead sponsor: Medtronic Surgical Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Boca Raton, Florida • Miami, Florida • Tampa, Florida

Conditions: Asthma
Interventions: Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more

Conditions: Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
Interventions: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more

Conditions: Diaphragm Paralysis
Interventions: interscalene nerve block with 0.25% bupivacaine, interscalene block with 0.125% bupivacaine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 8
States / cities: DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more

Conditions: Lung Transplant
Interventions: Belumosudil, Placebo for Belumosudil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 8 more

Conditions: Nasal Congestion and Inflammations, Sinus Congestion Chronic
Interventions: SinuSonic; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg, BD MDI 320 μg, FF MDI 9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 17
States / cities: Rolling Hills Estates, California • Clearwater, Florida • Panama City, Florida + 14 more

Conditions: Nasal Alar Collapse, Bilateral
Interventions: Polyester Implants; Device
Lead sponsor: Medtronic Xomed, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Sacramento, California • Atlanta, Georgia • Downers Grove, Illinois + 2 more

Search by objective public record fields.

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease

VivAer: A Correlation Between Symptom Scores and Objective Findings

Removal of Endotracheal Tube Secretions Comprehensively Until Extubation

A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Clearance Of Mucus In Stents (COMIS)

Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome

Acoustic Resonance Therapy for Treating Empty Nose Syndrome

Evaluation of Patients With Known or Suspected Heart Disease

Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Mild Valvar Pulmonary Stenosis

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

Novapak Prospective Observational Clinical Trial

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Effects of SinuSonic on Psychological and Physical Well-Being

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC)